Skip to main content
Find a Lawyer

Collaborative Research Agreement - Gilead Sciences Inc. and Glaxo Wellcome Inc.

                            AMENDMENT NO. 1
                    BETWEEN GILEAD SCIENCES, INC.
                        GLAXO WELLCOME INC.
                      DATED DECEMBER 22, 1997

This Amendment No. 1 (the 'Amendment') to the Collaborative Research 
Agreement entered into as of the 25th day of March, 1996, (the 'Original 
Agreement'), is made by and between GILEAD SCIENCES, INC., a Delaware 
corporation, having its principal place of business at 353 Lakeside Drive, 
Foster City, California, 94404 ('Gilead') and GLAXO WELLCOME INC., a North 
Carolina corporation, having offices at Five Moore Drive, Research Triangle 
Park, North Carolina 27709 ('Glaxo'), effective as of December 22, 1997.

WHEREAS, the Parties desire to amend the Original Agreement regarding Section 
13.4 'Termination of Research Term by Glaxo.'

NOW, THEREFORE, in consideration of the foregoing premises and of the mutual 
promises and covenants set forth below, for other good and valuable 
consideration the receipt and sufficiency of which the Parties acknowledge, 
and in accordance with Article 16.7 of the Original Agreement allowing 
modifications by written agreements duly signed by persons authorized to sign 
on behalf of the Parties, the Parties, intending to be legally bound, agree 
as follows:

1.  Unless otherwise defined in this Amendment, the capitalized terms used in 
this Amendment shall have the same meaning as given them in the Original 

2.  Article 13.4 shall be amended by deleting the first sentence of Article 
13.4 in its entirety and the following new first sentence of Article 13.4 
shall be inserted in lieu thereof:

    'Glaxo shall have the right to terminate the Research term prior to 
    expiration hereunder upon written notice to Gilead; provided, however, 
    that such termination be effective on the later of (a) June 22, 1998, or 
    (b) the date notice of termination pursuant to this Article 13.4 is given 
    to Gilead.'

3.  Except as modified above, the Original Agreement shall remain in full 
force and effect, including, but not limited to, the unamended provisions of 
Article 13.4.

IN WITNESS WHEREOF, the Parties have executed this Agreement, as of the day 
and year first above written.


By:  /s/ John C. Martin                  By:  /s/ Robert M. Bell
     ------------------------                 ------------------------

Name:  John C. Martin                    Name:  Robert M. Bell, Ph.D.
     ------------------------                 ------------------------

Title:  CEO                              Title:  Vice President, Research
                                                 Glaxo Wellcome Inc.
     ------------------------                 ------------------------


Was this helpful?

Copied to clipboard